APLS vs. SPY
Compare and contrast key facts about Apellis Pharmaceuticals, Inc. (APLS) and SPDR S&P 500 ETF (SPY).
SPY is a passively managed fund by State Street that tracks the performance of the S&P 500 Index. It was launched on Jan 22, 1993.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: APLS or SPY.
Key characteristics
| APLS | SPY | |
|---|---|---|
| YTD Return | -20.72% | 7.90% |
| 1Y Return | -43.75% | 28.03% |
| 3Y Return (Ann) | -1.53% | 8.75% |
| 5Y Return (Ann) | 19.39% | 13.52% |
| Sharpe Ratio | -0.52 | 2.33 |
| Daily Std Dev | 85.66% | 11.63% |
| Max Drawdown | -74.65% | -55.19% |
| Current Drawdown | -49.14% | -2.27% |
Correlation
The correlation between APLS and SPY is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
APLS vs. SPY - Performance Comparison
In the year-to-date period, APLS achieves a -20.72% return, which is significantly lower than SPY's 7.90% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
APLS vs. SPY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and SPDR S&P 500 ETF (SPY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
APLS vs. SPY - Dividend Comparison
APLS has not paid dividends to shareholders, while SPY's dividend yield for the trailing twelve months is around 1.31%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
APLS Apellis Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SPY SPDR S&P 500 ETF | 1.31% | 1.40% | 1.65% | 1.20% | 1.52% | 1.75% | 2.04% | 1.80% | 2.03% | 2.06% | 1.87% | 1.81% |
Drawdowns
APLS vs. SPY - Drawdown Comparison
The maximum APLS drawdown since its inception was -74.65%, which is greater than SPY's maximum drawdown of -55.19%. Use the drawdown chart below to compare losses from any high point for APLS and SPY. For additional features, visit the drawdowns tool.
Volatility
APLS vs. SPY - Volatility Comparison
Apellis Pharmaceuticals, Inc. (APLS) has a higher volatility of 17.27% compared to SPDR S&P 500 ETF (SPY) at 4.08%. This indicates that APLS's price experiences larger fluctuations and is considered to be riskier than SPY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.